SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive area for the treatment of diabetes. Join host Dr. Steven Edelman and his guest, professor of medicine at Tulane University, Dr. Vivian Fonseca, as they discuss the new class of medications being investigated for the treatment of type-2 diabetes.
Sodium-Glucose Transporters: A New Class of Diabetes Medications

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive area for the treatment of diabetes. Join host Dr. Steven Edelman and his guest, professor of medicine at Tulane University, Dr. Vivian Fonseca, as they discuss the new class of medications being investigated for the treatment of type-2 diabetes.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Updates From the 7th World Symposium Task Force
Diagnosis and Management of Metastatic PDAC
Chemotherapy Strategies for Metastatic PDAC
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
A Practical Guide to Prescribing in HF
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?